Challenges in TB regimen development: preserving evidentiary standards for regulatory decisions and policymaking-Reference-Cited by-同舟云学术

Challenges in TB regimen development: preserving evidentiary standards for regulatory decisions and policymaking

Published:2020-04-28 Issue:8 Volume:18 Page:701-704
ISSN:1478-7210
Container-title:Expert Review of Anti-infective Therapy
language:en
Short-container-title:Expert Review of Anti-infective Therapy

Author:

Guglielmetti Lorenzo¹²³,Low Marcus⁴⁵⁶,McKenna Lindsay⁵⁷

Affiliation:

1. Médecins Sans Frontières, Paris, France

2. Sorbonne Université, INSERM, U1135, Centre d’Immunologie Et Des Maladies Infectieuses, Paris, France

3. APHP, Groupe Hospitalier Universitaire Sorbonne Université, Hôpital Pitié-Salpêtrière, Centre National De Référence Des Mycobactéries Et De La Résistance Des Mycobactéries Aux Antituberculeux, Paris, France

4. Department of Computer Science, PhD Candidate, University of Cape Town, Cape Town, South Africa

5. Global Tuberculosis Community Advisory Board, New York, New York, USA

6. Spotlight, Cape Town, South Africa

7. Treatment Action Group, New York, USA

Publisher

Informa UK Limited

Subject

Virology,Infectious Diseases,Microbiology (medical),Microbiology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14787210.2020.1756776

Reference25 articles.

1. WHO. Global tuberculosis report 2019. Geneva World Health Organ. 2019;Licence: CC BY-NC-SA 3.0 IGO.

2. Burden of transmitted multidrug resistance in epidemics of tuberculosis: a transmission modelling analysis

3. Transmission of Extensively Drug-Resistant Tuberculosis in South Africa

4. Time to publication for results of clinical trials

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment of drug-susceptible and drug-resistant tuberculosis;The Challenge of Tuberculosis in the 21st Century;2023-09-01

2. Implementation challenges and lessons learned from the STREAM clinical trial—a survey of trial sites;Trials;2023-01-23

3. Comparing timelines and evidence available to support new TB, HIV, and HCV drug approvals: The same, only different;PLOS ONE;2022-07-25

4. Clinical Trials of TB: Challenges and Opportunities;Respiratory Disease Series: Diagnostic Tools and Disease Managements;2022

5. Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial;Trials;2021-09-25